Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal (opens in a new tab)

news-medical.net · 2026-10-16

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal

news-medical.net · 2026-10-16

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 8Not checkedinvIOs announced the publication of new clinical data on its autologous PBMC therapy APN401 in the peer-reviewed journal Molecular Therapy Oncology.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 8Not checkedThe publication, titled 'Phase I Evaluation of APN401, an Autologous CBL-B–Silenced PBMC Therapy, in Advanced Solid Tumors,' reports findings from two Phase 1 studies in patients with advanced, treatment-refractory solid tumors.View evidenceHide evidence

As statedtwo Phase 1 studies; 17 patients

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 8Not checkedA total of 17 patients received APN401 across three dose levels and had received between two and eleven prior lines of systemic therapy.View evidenceHide evidence

As stated17 patients; 2 to 11 prior lines of therapy

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 8Not checkedThe treatment was well tolerated, with no dose-limiting toxicities, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or grade ≥ 3 treatment-related adverse events.View evidenceHide evidence

As statedno DLTs; no CRS; no ICANS; no grade ≥ 3 TRAEs

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 8Not checkedThe highest dose of 4.5 × 10^7 PBMCs/kg was selected as the recommended Phase 2 dose.View evidenceHide evidence

As stated4.5 × 10^7 PBMCs/kg

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 6 of 8Not checkedDisease stabilization was observed in 5 out of 10 RECIST-evaluable patients.View evidenceHide evidence

As stated5 of 10 RECIST-evaluable patients

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 7 of 8Not checkedExploratory immune profiling found systemic changes after APN401, including increased cytotoxic mediators and expansion of specific T-cell populations, most pronounced in patients with stable disease.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 8 of 8Not checkedThe article says the findings support further clinical evaluation of APN401 and invIOs' EPiC platform, including reproducible manufacturing across sites and feasibility of repeated administration with a vein-to-vein time of less than 24 hours.View evidenceHide evidence

As statedless than 24 hours

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Phase I Evaluation of APN401, an Autologous CBL-B–Silenced PBMC Therapy, in Advanced Solid Tumors

Molecular Therapy Oncology · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, Europe PMC, PubMed · 40 candidate papers

Selected

Phase I Evaluation of APN401, an Autologous CBL-B–Silenced PBMC Therapy, in Advanced Solid Tumors

Molecular Therapy Oncology · 2026 · Crossref

Source (opens in a new tab)
Candidate

Abstract A033: Ex vivo Cbl-b silenced, autologous TIL therapy in glioblastoma demonstrates proof-of-concept efficacy and translational potential

Cancer Research · 2026 · Crossref

Source (opens in a new tab)
Candidate

Multidisciplinary Radiopharmaceutical Therapy Symposium (RPT): Author index

International Journal of Radiation Oncology*Biology*Physics · 2026 · Crossref

Source (opens in a new tab)

And 34 more candidates considered.